Plavix News and Research RSS Feed - Plavix News and Research

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada is aware of and will be reviewing new evidence on the safety of long-term use of the prescription blood-thinners clopidogrel (Plavix) and prasugrel (Effient). [More]
Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations. [More]
Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Researchers have identified the first genetic variations linked to race that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel (Plavix) after a heart attack. [More]
Medicare to pay for hep C screenings for baby boomers

Medicare to pay for hep C screenings for baby boomers

The decision comes amid controversy surrounding the costs of new drugs to treat the blood-borne virus. Meanwhile, two studies find that Medicare could save billions if doctors switched from an expensive eye medication to a similar, much cheaper one and, also, if Part D plans were selected based on the actual drugs patients take. [More]
Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013. [More]
Cardiologists question FDA recommendations on genetic testing before taking Plavix

Cardiologists question FDA recommendations on genetic testing before taking Plavix

Which antiplatelet medication is best after a coronary stent? The costly and potential life-or-death question lingers after most of the 600,000 angioplasties performed every year in the United States. The answer may lie in your genes, but professional cardiovascular societies and many working cardiologists question the U.S. Food and Drug Administration's recent recommendation that patients undergo genetic testing before taking Plavix (clopidogrel bisulfate). [More]
STSI receives $29M grant to support innovative research on genomics, wireless technology and bioinformatics

STSI receives $29M grant to support innovative research on genomics, wireless technology and bioinformatics

The National Institutes of Health has renewed its prestigious Clinical and Translational Science Award (CTSA) with the Scripps Translational Science Institute (STSI) in the amount of $29 million over the next five years to support innovative research in genomics, wireless technology and bioinformatics toward individualizing medicine. [More]
Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent. [More]
Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi US and POZEN Inc. announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet ("PA"), PA8140 and PA32540. [More]
Vanderbilt adds genetic screening for drug tacrolimus to PREDICT program

Vanderbilt adds genetic screening for drug tacrolimus to PREDICT program

Vanderbilt has added genetic screening for the drug tacrolimus to its personalize medicine pharmacogenomics program PREDICT. The new drug screening protocol was added following data that shows a single genetic variation largely impacts different dose requirements for patients. [More]
Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects. [More]
Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome. [More]
Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

One of the largest clinical trials done in infants with congenital (present at birth) heart diseases, published in the New England Journal of Medicine, shows that the increasingly common practice of using the drug clopidogrel (Plavix-) to reduce shunt-related blood flow issues is not effective in the dose studied. [More]
Study: New genetic marker predicts warfarin dose in African-Americans

Study: New genetic marker predicts warfarin dose in African-Americans

A newfound genetic marker promises to better predict warfarin dose in African-Americans, according to a study published online today in The Lancet. If confirmed in further studies, the finding may help to avert more of the bleeds and blood clots that come when a patient's starting dose misses the drug's narrow safety window. [More]
Study analyzes potential usefulness of new treatment to reopen clogged arteries

Study analyzes potential usefulness of new treatment to reopen clogged arteries

Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. [More]
Expiring patents drive drug spending's first time fall

Expiring patents drive drug spending's first time fall

Patient spending on prescription drugs fell in 2012 -- for the first time ever, a new study reports -- due in part to expiring patents on brand-name drugs. [More]
Study highlights cost savings of generic drugs

Study highlights cost savings of generic drugs

Consumer Reports offers new analysis that finds not all patients realize they can save big by shopping around for drugs. Meanwhile, two outlets look at insurance coverage issues for couples. [More]
University of Michigan Stroke Program study examines use of tPA in stroke patients

University of Michigan Stroke Program study examines use of tPA in stroke patients

Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots. [More]

Scientists demonstrate new approach for quickly assembling drug-like compounds

A team of scientists anchored at Yale University has demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment. [More]
Better understanding of clotting dynamics in atherosclerosis could lead to more effective drugs

Better understanding of clotting dynamics in atherosclerosis could lead to more effective drugs

The disease atherosclerosis involves the build up of fatty tissue within arterial walls, creating unstable structures known as plaques. These plaques grow until they burst, rupturing the wall and causing the formation of a blood clot within the artery. These clots also grow until they block blood flow; in the case of the coronary artery, this can cause a heart attack. [More]